Diagnosis and management of von willebrand disease: Guidelines for primary care

American Family Physician

Volumn 80, Issue 11, 2009, Pages

  Yawn, Barbara P ^a   Nichols, William L ^b   Rick, Margaret E ^c  

^a OLMSTED MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; DESMOPRESSIN; FIBRIN; THROMBIN; TRANEXAMIC ACID; VON WILLEBRAND FACTOR;

BLEEDING; CHILDBIRTH; DISEASE CLASSIFICATION; DRUG FORMULATION; FLUID RETENTION; HEMOSTASIS; HUMAN; HYSTERECTOMY; LABORATORY TEST; MENORRHAGIA; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREGNANCY; PRIMARY MEDICAL CARE; PROPHYLAXIS; PROTEIN BLOOD LEVEL; REVIEW; SIDE EFFECT; VON WILLEBRAND DISEASE;

EID: 72049130866     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Review

References (27)

1. Sadler JE, Mannucci PM, Berntorp E, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84(2):160-174. (Pubitemid 30601459)
2. Gill JC, Endres-Brooks J, Bauer PJ, et al. The effect of ABO blood group on the diagnosis of von Willebrand disease. Blood. 1987;69(6):1691-1695. (Pubitemid 17091627)
3. National Heart, Lung, and Blood Institute. The diagnosis, evaluation, and management of von Willebrand disease. Bethesda, Md.: National Institutes of Health; December 2007. NIH publication no. 08-5832. http://www.nhlbi.nih.gov/ guidelines/vwd. Accessed June 22, 2009.
4. National Heart, Lung, and Blood Institute. A pocket guide to the diagnosis, evaluation, and management of von Willebrand disease. Bethesda, Md.: National Institutes of Health; February 2008. NIH publication no. 08-5833. http://www.nhlbi.nih.gov/guidelines/vwd/vwd-pocketgde.htm. Accessed June 22, 2009.
5. Nichols WL, Hultin MB, James AH, et al. Von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). Haemophilia. 2008;14(2):171-232.
6. Ruggeri ZM, Ware J. von Willebrand factor. FASEB J. 1993;7(2):308-316.
7. Sadler JE, Budde U, Eikenboom JC, et al., for the Working Party on Von Willebrand Disease Classification. Update on the pathophysiology and classification of von Willebrand disease: a report of the Subcommittee on Von Willebrand Factor. J Thromb Haemost. 2006;4(10):2103-2114.
8. Mannucci PM. How I treat patients with von Willebrand disease. Blood. 2001;97(7):1915-1919. (Pubitemid 32239066)
9. Federici AB. Management of inherited von Willebrand disease in 2006. Semin Thromb Hemost. 2006;32(6):616-620. (Pubitemid 44453022)
10. Kumar S, Pruthi RK, Nichols WL. Acquired von Willebrand disease. Mayo Clin Proc. 2002;77(2):181-187.
11. Veyradier A, Jenkins CS, Fressinaud E, et al. Acquired von Willebrand syndrome: from pathophysiology to management. Thromb Haemost. 2000;84(2):175-182. (Pubitemid 30601460)
12. Srámek A, Eikenboom JC, Briët E, et al. Usefulness of patient interview in bleeding disorders. Arch Intern Med. 1995;155(13):1409-1415.
13. Warner PE, Critchley HO, Lumsden MA, et al. Menorrhagia I: measured blood loss, clinical features, and outcome in women with heavy periods. Am J Obstet Gynecol. 2004;190(5):1216-1223.
14. Chuong CJ, Brenner PF. Management of abnormal uterine bleeding. Am J Obstet Gynecol. 1996;175(3 pt 2):787-792.
15. Greer IA, Lowe GD, Walker JJ, et al. Haemorrhagic problems in obstetrics and gynaecology in patients with congenital coagulopathies. Br J Obstet Gynaecol. 1991;98(9):909-918.
16. Miller CH, Haff E, Platt SJ, et al. Measurement of von Willebrand factor activity. J Thromb Haemost. 2003;1(10):2191-2197.
17. Scott JP, Montgomery RR. Therapy of von Willebrand disease. Semin Thromb Hemost. 1993;19(1):37-47.
18. Federici AB, Sacco R, Stabile F, et al. Optimising local therapy during oral surgery in patients with von Willebrand disease: effective results from a retrospective analysis of 63 cases. Haemophilia. 2000;6(2):71-77. (Pubitemid 30166826)
19. Kirtava A, Crudder S, Dilley A, et al. Trends in clinical management of women with von Willebrand disease. Haemophilia. 2004;10(2):158-161.
20. Petitti DB. Clinical practice. Combination estrogen-progestin oral contraceptives [published correction appears in N Engl J Med. 2004; 350(1):92]. N Engl J Med. 2003;349(15):1443-1450.
21. Davis A, Godwin A, Lippman J, et al. Triphasic norgestimate-ethinyl estradiol for treating dysfunctional uterine bleeding. Obstet Gynecol. 2000;96(6):913-920. (Pubitemid 30838665)
22. Rubin G, Wortman M, Kouides PA. Endometrial ablation for von Willebrand disease-related menorrhagia-experience with seven cases. Haemophilia. 2004;10(5):477-482. (Pubitemid 39317757)
23. Kadir RA. Women and inherited bleeding disorders: pregnancy and delivery. Semin Hematol. 1999;36(3 suppl 4):28-35. (Pubitemid 29463584)
24. Kouides PA. Obstetric and gynaecological aspects of von Willebrand disease. Best Pract Res Clin Haematol. 2001;14(2):381-399. (Pubitemid 32677086)
25. Schafer AI. Effects of nonsteroidal antiinflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol. 1995;35(3):209-219.
26. Dahlman T, Hellgren M, Blombäck M. Changes in blood coagulation and fibrinolysis in the normal puerperium. Gynecol Obstet Invest. 1985;20(1):37-44. (Pubitemid 15015029)
27. Sánchez-Luceros A, Meschengieser SS, Marchese C, et al. Factor VIII and von Willebrand factor changes during normal pregnancy and puerperium. Blood Coagul Fibrinolysis. 2003;14(7):647-651. (Pubitemid 37323742)